2026-04-29T04:10:04Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/184582024-09-27T12:12:23Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Cattrini, Carlo author España, Rodrigo author Mennitto, Alessia author Bersanelli, Melissa author Castro, Elena author Olmos, David author Lorente, David author Gennari, Alessandra author 2021-09-08 The treatment landscape of advanced prostate cancer has completely changed during the last decades. Chemotherapy (docetaxel, cabazitaxel), androgen-receptor signaling inhibitors (ARSi) (abiraterone acetate, enzalutamide), and radium-223 have revolutionized the management of metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177-PSMA-617 is also going to become another treatment option for these patients. In addition, docetaxel, abiraterone acetate, apalutamide, enzalutamide, and radiotherapy to primary tumor have demonstrated the ability to significantly prolong the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Finally, apalutamide, enzalutamide, and darolutamide have recently provided impactful data in patients with nonmetastatic castration-resistant disease (nmCRPC). However, which is the best treatment sequence for patients with advanced prostate cancer? This comprehensive review aims at discussing the available literature data to identify the optimal sequencing approaches in patients with prostate cancer at different disease stages. Our work also highlights the potential impact of predictive biomarkers in treatment sequencing and exploring the role of specific agents (i.e., olaparib, rucaparib, talazoparib, niraparib, and ipatasertib) in biomarker-selected populations of patients with prostate cancer (i.e., those harboring alterations in DNA damage and response genes or PTEN). 2072-6694 http://hdl.handle.net/10668/18557 http://hdl.handle.net/20.500.12105/18458 34572748 10.3390/cancers13184522 Cancers LuPSMA PARP inhibitors androgen-receptor signaling inhibitors chemotherapy ipatasertib metastatic castration-resistant prostate cancer metastatic hormone-naïve prostate cancer metastatic hormone-sensitive prostate cancer nonmetastatic castration-resistant prostate cancer Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer.